mCRC QI Proposals

Receive up to $250,000 for your Quality Improvement Project Proposal Focused on Advancing Biomarker Testing in mCRC

There are significant advances in molecular diagnostics for metastatic colorectal cancer (mCRC), and these have been incorporated into NCCN Guidelines for frontline therapy. Despite such advances and guidelines, there is significant variability in biomarker testing practices and delays in communicating results that continue to hinder optimal patient treatment decision-making. Current protocols for ordering and reporting critical biomarkers are inconsistent across institutions, leading to gaps in diagnostic excellence and frontline therapy alignment with NCCN guidelines.

These challenges result in fragmented workflows, prolonged turnaround times, and insufficient coordination between pathology, laboratory professionals, and oncology teams. Consequently, patients may experience delays in receiving appropriate, evidence-based therapies.

To address these issues, there is an urgent need for collaborative, multidisciplinary initiatives that leverage data-driven approaches to:

ASCP will support collaborative approaches to improve processes and implement changes such as promoting standardized test ordering and reporting practices, providing data analysis, facilitating effective communication between pathology and oncology departments, and supporting the formation of molecular tumor boards to support multi-disciplinary decision-making and personalized patient care.

Best practices and lessons learned from the program will be published in peer-reviewed journals and relevant outlets to ensure broad visibility of your work.

Proposals must be submitted by March 31, 2026, to be considered.